Recombinant MVA vaccines: dispelling the myths.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Vaccine

• Publication date

  2013-09-06

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.vaccine.2013.03.021PMID 23523407
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase Ia Clinical Evaluation of the Safety and Immunogenicity of the Plasmodium falciparum Blood-Stage Antigen AMA1 in ChAd63 and MVA Vaccine Vectors

  2012cited by this paper
• Authentication of the R06E Fruit Bat Cell Line

  2012cited by this paper
• Vaccine Vectors Derived from a Large Collection of Simian Adenoviruses Induce Potent Cellular Immunity Across Multiple Species

  2012cited by this paper
• Expression and Cellular Immunogenicity of a Transgenic Antigen Driven by Endogenous Poxviral Early Promoters at Their Authentic Loci in MVA

  2012cited by this paper
• Novel Adenovirus-Based Vaccines Induce Broad and Sustained T Cell Responses to HCV in Man

  2012cited by this paper
• The Thai Phase III Trial (RV144) Vaccine Regimen Induces T Cell Responses That Preferentially Target Epitopes within the V2 Region of HIV-1 Envelope

  2012cited by this paper
• Clinical Assessment of a Recombinant Simian Adenovirus ChAd63: A Potent New Vaccine Vector

  2012cited by this paper
• Preventing spontaneous genetic rearrangements in the transgene cassettes of adenovirus vectors

  2012cited by this paper
• T‐cell‐inducing vaccines – what’s the future

  2012cited by this paper
• A chemically defined production process for highly attenuated poxviruses.

  2011cited by this paper
• Highly efficient, chemically defined and fully scalable biphasic production of vaccine viruses

  2011cited by this paper
• First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children.

  2011cited by this paper
• Genomic Analysis of the Vaccinia Virus Strain Variants Found in Dryvax Vaccine

  2011cited by this paper
• Avian cell line - Technology for large scale vaccine production

  2011cited by this paper
• Dual Neonate Vaccine Platform against HIV-1 and M. tuberculosis

  2011cited by this paper
• Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles.

  2011cited by this paper
• Viral vectors as vaccine platforms: deployment in sight.

  2011cited by this paper
• Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors.

  2011cited by this paper
• Potent CD8+ T-Cell Immunogenicity in Humans of a Novel Heterosubtypic Influenza A Vaccine, MVA−NP+M1

  2011cited by this paper
• MVA and NYVAC as vaccines against emergent infectious diseases and cancer.

  2011cited by this paper
• The Avian EB66(R) Cell Line, Application to Vaccines, and Therapeutic Protein Production.

  2010cited by this paper
• A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE.

  2010cited by this paper
• Phase III HIV vaccine trial in Thailand: a step toward a protective vaccine for HIV

  2010influential reference
• Cross-trial Analysis of Immunologic and Clinical Data Resulting From Phase I and II Trials of MVA-5T4 (TroVax) in Colorectal, Renal, and Prostate Cancer Patients

  2010cited by this paper
• Immediate-Early Expression of a Recombinant Antigen by Modified Vaccinia Virus Ankara Breaks the Immunodominance of Strong Vector-Specific B8R Antigen in Acute and Memory CD8 T-Cell Responses

  2010cited by this paper
• Correlates of Protection Induced by Vaccination

  2010cited by this paper
• Rapid generation of markerless recombinant MVA vaccines by en passant recombineering of a self-excising bacterial artificial chromosome.

  2010cited by this paper
• Purification of cell culture‐derived modified vaccinia ankara virus by pseudo‐affinity membrane adsorbers and hydrophobic interaction chromatography

  2010cited by this paper
• Evaluation of a modified vaccinia virus Ankara (MVA)-based candidate pandemic influenza A/H1N1 vaccine in the ferret model.

  2010cited by this paper
• Vaccination of Metastatic Renal Cancer Patients with MVA-5T4: A Randomized, Double-Blind, Placebo-Controlled Phase III Study

  2010cited by this paper
• Capturing of cell culture‐derived modified Vaccinia Ankara virus by ion exchange and pseudo‐affinity membrane adsorbers

  2009cited by this paper
• Modified vaccinia Ankara strains with identical coding sequences actually represent complex mixtures of viruses that determine the biological properties of each strain.

  2009cited by this paper
• Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A

  2009cited by this paper
• Modified vaccinia Ankara‐expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells

  2009cited by this paper
• Cell lines from the Egyptian fruit bat are permissive for modified vaccinia Ankara

  2009cited by this paper
• Poxvirus-vectored vaccines for rabies--a review.

  2009cited by this paper
• An avian cell line designed for production of highly attenuated viruses.

  2009cited by this paper
• Elucidating and Minimizing the Loss by Recombinant Vaccinia Virus of Human Immunodeficiency Virus Gene Expression Resulting from Spontaneous Mutations and Positive Selection

  2009cited by this paper
• Construction, Characterization, and Immunogenicity of a Multigene Modified Vaccinia Ankara (MVA) Vaccine Based on HIV Type 1 Subtype C

  2008cited by this paper
• Correlation of immunogenicities and in vitro expression levels of recombinant modified vaccinia virus Ankara HIV vaccines.

  2008cited by this paper
• Enhanced cell surface expression, immunogenicity and genetic stability resulting from a spontaneous truncation of HIV Env expressed by a recombinant MVA.

  2008cited by this paper
• Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial.

  2008cited by this paper
• HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis.

  2008cited by this paper
• Genomic sequence of chorioallantois vaccinia virus Ankara, the ancestor of modified vaccinia virus Ankara.

  2007cited by this paper
• Development and registration of recombinant veterinary vaccines. The example of the canarypox vector platform.

  2007cited by this paper
• Genetic stability of recombinant MVA-BN.

  2006cited by this paper
• Immunogenicity of the candidate malaria vaccines FP9 and modified vaccinia virus Ankara encoding the pre-erythrocytic antigen ME-TRAP in 1-6 year old children in a malaria endemic area.

  2006cited by this paper
• Recombinant viral vectors: cancer vaccines.

  2006cited by this paper
• Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis.

  2006cited by this paper
• Vaccination of Colorectal Cancer Patients with Modified Vaccinia Ankara Delivering the Tumor Antigen 5T4 (TroVax) Induces Immune Responses which Correlate with Disease Control: A Phase I/II Trial

  2006cited by this paper
• Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara.

  2005cited by this paper
• Fowlpox virus as a recombinant vaccine vector for use in mammals and poultry

  2005cited by this paper
• Modified vaccinia Ankara: potential as an alternative smallpox vaccine.

  2004cited by this paper
• Comparison of the genome sequence of FP9, an attenuated, tissue culture-adapted European strain of Fowlpox virus, with those of virulent American and European viruses.

  2004cited by this paper
• Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men.

  2004cited by this paper
• Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery.

  2003cited by this paper
• Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine.

  1998cited by this paper
• Marker rescue of the host range restriction defects of modified vaccinia virus Ankara.

  1998cited by this paper
• Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells.

  1998cited by this paper
• The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses.

  1998cited by this paper
• Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line.

  1997cited by this paper
• Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model.

  1996cited by this paper
• Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates.

  1996cited by this paper
• Removal of cryptic poxvirus transcription termination signals from the human immunodeficiency virus type 1 envelope gene enhances expression and immunogenicity of a recombinant vaccinia virus

  1990cited by this paper
• Construction of live vaccines by using genetically engineered poxviruses: biological activity of recombinant vaccinia virus expressing influenza virus hemagglutinin.

  1983cited by this paper
• Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen

  1983cited by this paper
• Construction and characterization of an infectious vaccinia virus recombinant that expresses the influenza hemagglutinin gene and induces resistance to influenza virus infection in hamsters.

  1983cited by this paper
• [The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl)].

  1978cited by this paper
• Abstammung, Eigenschaften und Verwendung des attenuierten Vaccinia-Stammes MVA

  1975cited by this paper

• Strong immunogenicity and protection against SARS-CoV-2 in hamsters induced by heterologous boost vaccination with an MVA-based COVID-19 vaccine candidate

  2025cites this paper
• Plattformtechnologien in der Impfstoffentwicklung

  2025cites this paper
• A Brighton collaboration standardized template with key considerations for a benefit/risk assessment for a viral vector vaccine based on a non-replicating modified vaccinia virus Ankara viral vector.

  2024cites this paper
• Multivalent MVA-vectored vaccine elicits EBV neutralizing antibodies in rhesus macaques that reduce EBV infection in humanized mice

  2024cites this paper
• Highly stable and immunogenic CMV T cell vaccine candidate developed using a synthetic MVA platform

  2024cites this paper
• A Novel Recombinant Modified Vaccinia Ankara Virus expressing Interleukin-13 Receptor α2 Antigen for Potential Cancer Immunotherapy.

  2023cites this paper
• Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases

  2023cites this paper
• Adenoviral vectored vaccination protects against Crimean-Congo Haemorrhagic Fever disease in a lethal challenge model

  2023cites this paper
• Comparison of the oncolytic activity of recombinant vaccinia virus strains LIVP-RFP and MVA-RFP against solid tumors

  2023cites this paper
• Reflections on the Social Determinants of the COVID-19 Vaccination Programme in Zimbabwe

  2023cites this paper
• Vector Aided Microenvironment programming (VAMP): reprogramming the TME with MVA virus expressing IL-12 for effective antitumor activity

  2023cites this paper
• Development of Modified Vaccinia Virus Ankara-Based Vaccines: Advantages and Applications

  2022cites this paper
• Modified vaccinia Ankara expressing EEHV1A glycoprotein B elicits humoral and cell-mediated immune responses in mice

  2022cites this paper
• Genetic stability of SIV Gag/Tat gene inserted into Del-II in Modified Vaccinia Virus Ankara After Serial Passage of Recombinant Vector in pCEFs Cells.

  2022cites this paper
• Single Immunization with Recombinant ACAM2000 Vaccinia Viruses Expressing the Spike and the Nucleocapsid Proteins Protects Hamsters against SARS-CoV-2-Caused Clinical Disease

  2022cites this paper
• Crimean-Congo hemorrhagic fever virus vaccine: past, present, and future

  2021cites this paper
• [Review of candidate vaccines for the prevention of Lassa fever].

  2021cites this paper
• Advancements in the Growth and Construction of Recombinant Lumpy Skin Disease Virus (LSDV) for Use as a Vaccine Vector

  2021cites this paper
• Korea vaccinia viral vectored vaccine expressing 33 kDa fragment of Plasmodium vivax merozoite surface protein 1 elicited strong humoral immune responses in mice

  2021cites this paper
• Обзор кандидатных вакцин для профилактики лихорадки Review of candidate vaccines for the prevention of Lassa fever

  2021cites this paper
• Epicutaneous immunization with modified vaccinia Ankara viral vectors generates superior T cell immunity against a respiratory viral challenge

  2021cites this paper
• Skin Delivery of Modified Vaccinia Ankara Viral Vectors Generates Superior T Cell Immunity Against a Respiratory Viral Challenge

  2020cites this paper
• Development of a multi-antigenic SARS-CoV-2 vaccine candidate using a synthetic poxvirus platform

  2020cites this paper
• Heterologous prime-boost immunization co-targeting dual antigens inhibit tumor growth and relapse

  2020influential citation
• Optimising T cell (re)boosting strategies for adenoviral and modified vaccinia Ankara vaccine regimens in humans

  2020cites this paper
• The Brighton Collaboration standardized template for collection of key information for risk/benefit assessment of a Modified Vaccinia Ankara (MVA) vaccine platform

  2020cites this paper
• Advancing Immunotherapeutic Vaccine Strategies Against Pulmonary Tuberculosis

  2020cites this paper
• Development of a Multi-Antigenic SARS-CoV-2 Vaccine Using a Synthetic Poxvirus Platform

  2020cites this paper
• Development of a Synthetic Poxvirus-Based SARS-CoV-2 Vaccine

  2020cites this paper
• MVA Vectored Vaccines Encoding Rift Valley Fever Virus Glycoproteins Protect Mice against Lethal Challenge in the Absence of Neutralizing Antibody Responses

  2020cites this paper
• When Cancer Vaccines Go Viral

  2019cites this paper
• Comparison of Dendritic Cell Activation by Virus-Based Vaccine Delivery Vectors Emphasizes the Transcriptional Downregulation of the Oxidative Phosphorylation Pathway

  2019cites this paper
• Viral Replicative Capacity, Antigen Availability via Hematogenous Spread, and High TFH:TFR Ratios Drive Induction of Potent Neutralizing Antibody Responses

  2019cites this paper
• Recombinant influenza A viruses as vaccine vectors

  2019cites this paper
• Risk factors for communicable diseases in humanitarian emergencies and disasters: Results from a three-stage expert elicitation

  2019cites this paper
• Safety and Immunogenicity of the Heterosubtypic Influenza A Vaccine MVA-NP+M1 Manufactured on the AGE1.CR.pIX Avian Cell Line

  2019cites this paper
• Viral Vectors for Treatment of Human Disease: Therapeutic and Manufacturing Challenges

  2019cites this paper
• Dissecting the heterogeneity of DENV vaccine-elicited cellular immunity using single-cell RNA sequencing and cellular metabolic profiling

  2019cites this paper
• A Genome-Wide Haploid Genetic Screen Identifies Heparan Sulfate-Associated Genes and the Macropinocytosis Modulator TMED10 as Factors Supporting Vaccinia Virus Infection

  2019cites this paper
• Development of novel vaccines against human cytomegalovirus

  2019cites this paper
• A vaccine based on recombinant modified Vaccinia Ankara containing the nucleoprotein from Lassa virus protects against disease progression in a guinea pig model.

  2019cites this paper
• Dissecting the heterogeneity of DENV vaccine-elicited cellular immunity using single-cell RNA sequencing and metabolic profiling

  2019cites this paper
• Interleukin-21 enhances the antibody avidity elicited by DNA prime and MVA boost vaccine.

  2019cites this paper
• African Horse Sickness: A Review of Current Understanding and Vaccine Development

  2019cites this paper
• Sequestration of Late Antigens Within Viral Factories Impairs MVA Vector-Induced Protective Memory CTL Responses

  2019cites this paper
• A Deleted Deletion Site in a New Vector Strain and Exceptional Genomic Stability of Plaque-Purified Modified Vaccinia Ankara (MVA)

  2019cites this paper
• ORF6 and ORF61 Expressing MVA Vaccines Impair Early but Not Late Latency in Murine Gammaherpesvirus MHV-68 Infection

  2019cites this paper
• Vaccinia-based vaccines to biothreat and emerging viruses

  2018cites this paper
• A fifty-year odyssey: prospects for a cytomegalovirus vaccine in transplant and congenital infection

  2018cites this paper
• Chapter 2 Prophylactic and Therapeutic Vaccines against Human Papillomavirus Infections

  2018cites this paper
• A genome-wide haploid genetic screen for essential factors in vaccinia virus infection identifies TMED10 as regulator of macropinocytosis

  2018cites this paper
• Multiantigenic Modified Vaccinia Virus Ankara Vaccine Vectors To Elicit Potent Humoral and Cellular Immune Reponses against Human Cytomegalovirus in Mice

  2018cites this paper
• Prophylactic and Therapeutic Vaccines against Human Papillomavirus Infections

  2017cites this paper
• Comparison of homologous and heterologous prime-boost immunizations combining MVA-vectored and plant-derived VP2 as a strategy against IBDV.

  2017cites this paper
• Microspheres‐prime/rMVA‐boost vaccination enhances humoral and cellular immune response in IFNAR(−/−) mice conferring protection against serotypes 1 and 4 of bluetongue virus

  2017cites this paper
• A novel strategy to express different antigens from one modified vaccinia Ankara vaccine vector

  2017cites this paper
• Vaccination with recombinant Modified Vaccinia Ankara (MVA) viruses expressing single African horse sickness virus VP2 antigens induced cross-reactive virus neutralising antibodies (VNAb) in horses when administered in combination.

  2017cites this paper
• Development of vaccines against Crimean-Congo haemorrhagic fever virus

  2017cites this paper
• Immunogenicity and efficacy of DNA/MVA HIV vaccines in rhesus macaque models

  2017cites this paper
• Hazard Characterization of Modified Vaccinia Virus Ankara Vector: What Are the Knowledge Gaps?

  2017influential citation
• Desarrollo de vacunas recombinantes marcadoras multiserotipo frente al virus de la lengua azul

  2017influential citation
• MVA vaccine encoding CMV antigens safely induces durable expansion of CMV-specific T cells in healthy adults.

  2017influential citation
• Induction of Both Local Immune Response in Mice and Protection in a Rabbit Model by Intranasal Immunization with Modified Vaccinia Ankara Virus Expressing a Secreted Form of Bovine Herpesvirus 1 Glycoprotein D

  2017cites this paper
• Acute Virus Infections in Paediatric Patients Admitted to Intensive Care

  2016cites this paper
• Therapeutic vaccination strategies to treat nasopharyngeal carcinoma.

  2016cites this paper
• Untersuchung rekombinanter Modifizierter Vacciniaviren Ankara hinsichtlich ihrer Eignung als Hendra-Virus-spezifische Impfstoffkandidaten

  2016cites this paper
• Cross-Sectoral Perspectives of Market Implementation of the MVA Platform forInfluenza Vaccines: Regulatory, Industry and Academia

  2016cites this paper
• Vector-based genetically modified vaccines: Exploiting Jenner’s legacy

  2016cites this paper
• The EB66® cell line as a valuable cell substrate for MVA-based vaccines production.

  2016cites this paper
• Ebola virus disease candidate vaccines under evaluation in clinical trials

  2016cites this paper
• A MVA construct expressing a secretable form of the Dengue virus 3 envelope protein protects immunized mice from dengue-induced encephalitis.

  2016cites this paper
• Development of Newer Smallpox Vaccines

  2016cites this paper
• Disruptive Innovation by Genetic Modification Technology as a Market Driver to Target Unmet Vaccine Needs: Influenza in the Limelight

  2016influential citation
• A multipathogen vaccine for rabies, hepatitis B, Japanese encephalitis and enterovirus 71

  2016cites this paper
• Genome sequence and comparative virulence of raccoonpox virus: the first North American poxvirus sequence.

  2015cites this paper
• The Evolution of Poxvirus Vaccines

  2015cites this paper
• Large-scale adenovirus and poxvirus-vectored vaccine manufacturing to enable clinical trials.

  2015cites this paper
• Filling the Immunological Gap: Recombinant Viral Vectors for Mucosal Vaccines

  2015cites this paper
• Purification of modified vaccinia virus Ankara from suspension cell culture

  2015cites this paper
• Recombinant rubella vectors elicit SIV Gag-specific T cell responses with cytotoxic potential in rhesus macaques.

  2015cites this paper
• A Crimean-Congo hemorrhagic fever (CCHF) viral vaccine expressing nucleoprotein is immunogenic but fails to confer protection against lethal disease

  2015cites this paper
• Gene Transfer for Prophylaxis and Therapy of Viral Infections

  2015cites this paper
• Market implementation of the MVA platform for pre-pandemic and pandemic influenza vaccines: A quantitative key opinion leader analysis

  2015cites this paper
• Genetic and molecular technologies to optimise novel vaccines for Hepatitis C virus infection

  2015cites this paper
• Regression of Human Papillomavirus Intraepithelial Lesions Is Induced by MVA E2 Therapeutic Vaccine

  2014cites this paper
• InfectionMice against Chikungunya MVA-CHIKV, Is Highly Immunogenic and A Novel Poxvirus-Based Vaccine,

  2014cites this paper
• Enhancing poxvirus vectors vaccine immunogenicity

  2014cites this paper
• Modified vaccinia virus Ankara as vaccine vectors in human and veterinary medicine

  2014cites this paper
• A Novel MVA Vectored Chikungunya Virus Vaccine Elicits Protective Immunity in Mice

  2014cites this paper
• Leukocyte trafficking during infection with modified vaccinia virus Ankara

  2014cites this paper
• Alphavirus replicon-based strategies for vaccination

  2014cites this paper
• Design of recombinant vaccines for Gumboro, Newcastle and Avian Infectious Laryngotracheitis

  2014cites this paper
• Deletion of the Vaccinia Virus N2L Gene Encoding an Inhibitor of IRF3 Improves the Immunogenicity of Modified Vaccinia Virus Ankara Expressing HIV-1 Antigens

  2014cites this paper
• A Novel Poxvirus-Based Vaccine, MVA-CHIKV, Is Highly Immunogenic and Protects Mice against Chikungunya Infection

  2014cites this paper
• A Novel Vaccine against Crimean-Congo Haemorrhagic Fever Protects 100% of Animals against Lethal Challenge in a Mouse Model

  2014cites this paper
• Diseño de vacunas recombinantes en las enfermedades de Gumboro, Newcastle y Laringotraqueítis Infecciosa Aviar

  2014cites this paper
• Human immunodeficiency virus infection/acquired immunodeficiency syndrome Vaccine: Biggest challenge in medical sciences - Some see a hopeless end, while others see an endless hope

  2014cites this paper
• Prediction of Steps in the Evolution of Variola Virus Host Range

  2014cites this paper
• 8th International Conference on Oncolytic Virus Therapeutics

  2014cites this paper
• Leukocyte trafficking during infection with Modified Vaccinia virus Ankara: the role of chemokine receptor 1 and complement activation

  2014cites this paper